Towards the use of cannabinoids as antitumour agents

Nature Reviews Cancer

Volumn 12, Issue 6, 2012, Pages 436-444

  Velasco, Guillermo ^a,b,c   Sánchez, Cristina ^a   Guzmán, Manuel ^a,b,d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; DRONABINOL; ENDOCANNABINOID; NABILONE; NABIXIMOLS; TEMOZOLOMIDE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RESEARCH; CELL DEATH; DRUG MECHANISM; DRUG RESEARCH; ENDOPLASMIC RETICULUM STRESS; GLIOMA; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; CELL DEATH; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCANNABINOIDS; HUMANS; NEOPLASMS;

EID: 84861530762     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3247     Document Type: Review

References (100)

1. Gaoni, Y. & Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647 (1964).
2. Pertwee, R. G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215 (2008).
3. Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992). (Pubitemid 23026736)
4. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90 (1995).
5. Sugiura, T. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97 (1995).
6. Pertwee, R. G. et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631 (2010).
7. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
8. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993). (Pubitemid 23305569)
9. Fernandez-Ruiz, J. et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28, 39-45 (2007). (Pubitemid 46038536)
10. Atwood, B. K. & Mackie, K. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 160, 467-479 (2010).
11. Guzman, M. et al. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer 95, 197-203 (2006). (Pubitemid 44050919)
12. Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F. & Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 68, 339-342 (2008). (Pubitemid 351380057)
13. Katona, I. & Freund, T. F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nature Med. 14, 923-930 (2008).
14. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389-462 (2006). (Pubitemid 44394908)
15. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411 (2009).
16. Guzman, M. Cannabinoids: potential anticancer agents. Nature Rev. Cancer 3, 745-755 (2003). (Pubitemid 37328813)
17. Cudaback, E., Marrs, W., Moeller, T. & Stella, N. The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS ONE 5, e8702 (2010).
18. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64, 1943-1950 (2004). (Pubitemid 38339438)
19. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Δ9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174, 3281-3289 (2005). (Pubitemid 40354031)
20. Zhu, L. X. et al. Δ9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. 165, 373-380 (2000). (Pubitemid 30429529)
21. Malfitano, A. M. et al. Update on the endocannabinoid system as an anticancer target. Expert Opin. Ther. Targets. 15, 297-308 (2011).
22. Caffarel, M. M., Sarrio, D., Palacios, J., Guzman, M. & Sanchez, C. Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 66, 6615-6621 (2006). (Pubitemid 44085617)
23. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 61, 5784-5789 (2001). (Pubitemid 32769095)
24. Nomura, D. K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61 (2010).
25. Thors, L. et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS ONE 5, e12275 (2010).
26. Zheng, D. et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res. 68, 3992-3998 (2008).
27. Joosten, M. et al. Leukemic predisposition of pSca-1/Cb2 transgenic mice. Exp. Hematol. 30, 142-149 (2002). (Pubitemid 34081225)
28. Wang, D. et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 68, 6468-6476 (2008).
29. Izzo, A. A. et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med. (Berl.) 86, 89-98 (2008).
30. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 64, 5617-5623 (2004). (Pubitemid 39095557)
31. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med. 6, 313-319 (2000). (Pubitemid 30148624)
32. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. & Guzman, M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem. J. 363, 183-188 (2002). (Pubitemid 34280625)
33. Carracedo, A. et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301-312 (2006).
34. Encinar, J. A. et al. Human p8 is a HMG-I/Y-like protein with DNA binding activity enhanced by phosphorylation. J. Biol. Chem. 276, 2742-2751 (2001).
35. Schroder, M. & Kaufman, R. J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789 (2005). (Pubitemid 40995523)
36. Verfaillie, T., Salazar, M., Velasco, G. & Agostinis, P. Linking ER stress to autophagy: potential implications for cancer therapy. Int. J. Cell Biol. 2010, 930509 (2010).
37. Mizushima, N., Levine, B., Cuervo, A. M. & Klionsky, D. J. Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075 (2008). (Pubitemid 351317450)
38. Eisenberg-Lerner, A., Bialik, S., Simon, H. U. & Kimchi, A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 16, 966-975 (2009).
39. Salazar, M. et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119, 1359-1372 (2009).
40. Vara, D. et al. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 18, 1099-1111 (2011).
41. Carracedo, A. et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 66, 6748-6755 (2006). (Pubitemid 44085633)
42. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633-2635 (2006).
43. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J. Biol. Chem. 281, 39480-39491 (2006). (Pubitemid 46041908)
44. Guindon, J. & Hohmann, A. G. The endocannabinoid system and cancer: therapeutic implication. Br. J. Pharmacol. 163, 1447-1463 (2011).
45. Ligresti, A. et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318, 1375-1387 (2006). (Pubitemid 44268348)
46. Massi, P. et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J. Neurochem. 104, 1091-1100 (2008). (Pubitemid 351143654)
47. Shrivastava, A., Kuzontkoski, P. M., Groopman, J. E. & Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol. Cancer Ther. 10, 1161-1172 (2011).
48. Massi, P. et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cel. Mol. Life Sci. 63, 2057-2066 (2006). (Pubitemid 44359745)
49. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43-50 (2003).
50. Blazquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17, 529-531 (2003).
51. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17, 1771-1773 (2003).
52. Pisanti, S. et al. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J. Cell Physiol. 211, 495-503 (2007). (Pubitemid 46580103)
53. Blazquez, C. et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 68, 1945-1952 (2008). (Pubitemid 351416581)
54. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res. 312, 363-373 (2006). (Pubitemid 41804104)
55. Qamri, Z. et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol. Cancer Ther. 8, 3117-3129 (2009).
56. Preet, A., Ganju, R. K. & Groopman, J. E. Δ9- tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27, 339-346 (2008).
57. Ramer, R. & Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 100, 59-69 (2008). (Pubitemid 351767340)
58. McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A. & Desprez, P. Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol. Cancer Ther. 6, 2921-2927 (2007). (Pubitemid 350206770)
59. McAllister, S. D. et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res. Treat. 129, 37-47 (2011).
60. Galve-Roperh, I., Aguado, T., Palazuelos, J. & Guzman, M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des. 14, 2279-2288 (2008).
61. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and carcinogenicity of Δ9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam. Appl. Toxicol. 30, 109-117 (1996).
62. Lombard, C., Nagarkatti, M. & Nagarkatti, P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin. Immunol. 122, 259-270 (2007). (Pubitemid 46216921)
63. Rieder, S. A., Chauhan, A., Singh, U., Nagarkatti, M. & Nagarkatti, P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215, 598-605 (2010).
64. Lorente, M. et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ. 18, 959-973 (2011).
65. Newton, C. A., Chou, P. J., Perkins, I. & Klein, T. W. CB1 and CB2 cannabinoid receptors mediate different aspects of Δ9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J. Neuroimmune Pharmacol. 4, 92-102 (2009).
66. Lu, T., Newton, C., Perkins, I., Friedman, H. & Klein, T. W. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J. Pharmacol. Exp. Ther. 319, 269-276 (2006). (Pubitemid 44455132)
67. Steffens, S. et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786 (2005). (Pubitemid 44739523)
68. Hegde, V. L., Nagarkatti, M. & Nagarkatti, P. S. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur. J. Immunol. 40, 3358-3371 (2010).
69. Burstein, S. H. & Zurier, R. B. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 11, 109-119 (2009).
70. Liu, W. M., Fowler, D. W. & Dalgleish, A. G. Cannabis-derived substances in cancer therapy-an emerging anti-inflammatory role for the cannabinoids. Curr. Clin. Pharmacol. 5, 281-287 (2010).
71. Hudson, B. D., Hebert, T. E. & Kelly, M. E. Ligand-and heterodimer-directed signaling of the CB1 cannabinoid receptor. Mol. Pharmacol. 77, 1-9 (2010).
72. Dainese, E., Oddi, S. & Maccarrone, M. Interaction of endocannabinoid receptors with biological membranes. Curr. Med. Chem. 17, 1487-1499 (2010).
73. Smith, T. H., Sim-Selley, L. J. & Selley, D. E. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br. J. Pharmacol. 160, 454-466 (2010).
74. Mirkin, B. L. et al. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 24, 4965-4974 (2005). (Pubitemid 41129100)
75. Kadomatsu, K. The midkine family in cancer, inflammation and neural development. Nagoya J. Med. Sci. 67, 71-82 (2005).
76. Palmer, R. H., Vernersson, E., Grabbe, C. & Hallberg, B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 420, 345-361 (2009).
77. de Bono, J. S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature 467, 543-549 (2010).
78. Grande, E., Bolos, M. V. & Arriola, E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol. Cancer Ther. 10, 569-579 (2011).
79. Lorente, M. et al. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia 57, 1374-1385 (2009).
80. Torres, S. et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 10, 90-103 (2011).
81. Donadelli, M. et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2, e152 (2011).
82. Miyato, H. et al. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J. Surg. Res. 155, 40-47 (2009).
83. Gustafsson, S. B., Lindgren, T., Jonsson, M. & Jacobsson, S. O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother. Pharmacol. 63, 691-701 (2009).
84. Marcu, J. P. et al. Cannabidiol enhances the inhibitory effects of Δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther. 9, 180-189 (2010).
85. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15, 2745-2747 (2001).
86. Herrera, B. et al. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp. Cell Res. 312, 2121-2131 (2006). (Pubitemid 43850936)
87. Du, K., Herzig, S., Kulkarni, R. N. & Montminy, M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300, 1574-1577 (2003). (Pubitemid 36682889)
88. Ellert-Miklaszewska, A., Kaminska, B. & Konarska, L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 17, 25-37 (2005). (Pubitemid 39286777)
89. Caffarel, M. M. et al. JunD is involved in the antiproliferative effect of Δ9-tetrahydrocannabinol on human breast cancer cells. Oncogene 27, 5033-5044 (2008).
90. Lonardi, S., Tosoni, A. & Brandes, A. A. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat. Rev. 31, 79-89 (2005). (Pubitemid 40542887)
91. Nieder, C., Adam, M., Molls, M. & Grosu, A. L. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol. 60, 181-193 (2006). (Pubitemid 44709618)
92. Purow, B. & Schiff, D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nature Rev. Neurol. 5, 419-426 (2009).
93. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005). (Pubitemid 40349501)
94. Caffarel, M. M. et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol. Cancer 9, 196 (2010).
95. Oesch, S. et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol. Cancer Ther. 8, 1838-1845 (2009).
96. Gustafsson, K., Christensson, B., Sander, B. & Flygare, J. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol. Pharmacol. 70, 1612-1620 (2006).
97. McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634 (2002). (Pubitemid 34761128)
98. Jia, W. et al. Δ9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol. Cancer Res. 4, 549-562 (2006). (Pubitemid 44341365)
99. Mimeault, M., Pommery, N., Wattez, N., Bailly, C. & Henichart, J. P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56, 1-12 (2003). (Pubitemid 36613150)
100. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br. J. Cancer 101, 940-950 (2009).